anti-inflammatory therapies - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.01 [0.93, 1.10]< 10%1 study (1/-)40.8 %some concernnot evaluable moderatecrucial-
deaths 1.01 [0.93, 1.10]< 10%3 studies (3/-)42.8 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.11 [0.01, 1.08]< 10%1 study (1/-)97.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.17 [0.02, 1.48]< 10%1 study (1/-)94.5 %some concernnot evaluable moderateimportant-

safety endpoints 00

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.